Loading organizations...
I am unable to complete this request because I am consistently receiving "429 Too Many Requests" errors when attempting to fetch content from the web pages. This technical issue prevents me from gathering the necessary information to thoroughly research Sooma and write the company profile as specified.
Sooma has raised $5.0M across 1 funding round.
Sooma has raised $5.0M in total across 1 funding round.
Sooma has raised $5.0M in total across 1 funding round.
Sooma's investors include Rockstart, Voima Ventures.
Sooma has raised $5.0M across 1 funding round. Most recently, it raised $5.0M Seed in March 2024.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Mar 1, 2024 | $5M Seed | — | Rockstart, Voima Ventures | Announced |
Sooma Medical is a Finnish medtech company founded in 2013 that develops, manufactures, and markets portable, non-invasive transcranial direct current stimulation (tDCS) devices for treating major depressive disorder (MDD), chronic pain conditions like fibromyalgia and neuropathic pain, and other neurological/psychiatric disorders[1][2][3][6]. Its flagship products, such as Sooma tDCS and the 2023-launched Sooma Duo, serve clinics, hospitals, and now direct-to-patient models in select markets, solving the problem of limited access to drug-free, opiate-free therapies amid strained healthcare resources and long waiting times[2][3][7]. With EU MDR approval, ISO 13485 manufacturing, and over 30,000 patients treated across 35+ countries in 250+ clinics, Sooma holds the position of the world's most prescribed tDCS therapy, demonstrating strong growth including FDA Breakthrough Device designation in 2023 and clinical trial approval in 2025[1][2][3][7].
Sooma Oy was established in 2013 in Helsinki, Finland, by co-founders Tuomas Neuvonen (CEO) and Jani Virtanen (Board Member), with key early leaders like Mika Nikander (COO), Maria Kivistö (R&D Manager), and later Peter Hilgert (Chief Commercial Officer)[1][6]. The idea emerged from collaboration with leading psychiatry and clinical neurophysiology experts to address unmet needs in treating depression and chronic pain through science-backed neuromodulation, starting with the first-generation Sooma tDCS device launched in 2014 for MDD[3][6]. Pivotal moments include the 2017 expansion to Sooma Pain Therapy, reaching 20,000+ prescriptions by end-2023, the 2023 Sooma Duo launch with digital platform integration, and regulatory wins like EU MDR certification and U.S. FDA Breakthrough status, enabling global traction from 150+ centers in 35 countries[1][3][7].
Sooma rides the wave of non-invasive neuromodulation and digital therapeutics, addressing global mental health crises—depression affects millions—with drug-free alternatives amid opioid epidemics and pharma resistance[1][4][7]. Timing aligns with post-pandemic demand for accessible care, remote monitoring tech, and regulatory shifts favoring breakthrough devices, amplified by telemedicine growth and healthcare digitization[1][3]. Market tailwinds include rising chronic pain/depression prevalence, clinician shortages, and payer interest in cost-effective outpatient solutions; Sooma influences the ecosystem by normalizing tDCS in 35+ countries, partnering with 250+ clinics, and paving U.S. entry, challenging incumbents and expanding non-pharma options[2][5][7].
Sooma is primed for U.S. market penetration post-2025 FDA trial approval, potentially scaling to match its European dominance with Sooma Duo's direct-to-patient push amid global mental health funding surges[1][7]. Trends like AI-enhanced neuromodulation, personalized brain health platforms, and expanded indications (e.g., beyond depression/pain) will shape its path, with influence growing via IP strength and clinician networks to redefine accessible psychiatry. As the tDCS leader democratizing brain stimulation, Sooma exemplifies medtech's shift toward patient-empowered, non-drug innovation—positioning it to touch millions more lives[2][3].
